PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPergolide
Pergolide
Permax (pergolide) is a small molecule pharmaceutical. Pergolide was first approved as Permax on 1988-12-30. It is used to treat parkinson disease and tourette syndrome in the USA. It is known to target 5-hydroxytryptamine receptor 2B, alpha-2B adrenergic receptor, D(3) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1D, D(1A) dopamine receptor, D(1B) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2C, alpha-2C adrenergic receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 7, alpha-2A adrenergic receptor, and 5-hydroxytryptamine receptor 6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pergolide mesylate
Tradename
Company
Number
Date
Products
PERMAXBausch Health CompaniesN-019385 DISCN1988-12-30
3 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
permax2007-03-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
parkinson diseaseEFO_0002508D010300G20
tourette syndromeEFO_0004895D005879F95.2
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04B: Dopaminergic agents
— N04BC: Dopamine agonists
— N04BC02: Pergolide
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20——1—45
Cocaine-related disordersD019970—F14—21——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Substance-related disordersD019966EFO_0003890F13—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20————22
Heart valve diseasesD006349EFO_0009551I08————22
Cognitive dysfunctionD060825HP_0001268G31.84————11
FibrosisD005355——————11
Neurobehavioral manifestationsD019954EFO_0004364—————11
Schizotypal personality disorderD012569—F21————11
Personality disordersD010554HP_0012075F60.6————11
Tourette syndromeD005879EFO_0004895F95.2————11
SyndromeD013577——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePergolide
INNpergolide
Description
Pergolide is a diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. It has a role as an antiparkinson drug and a dopamine agonist. It is a diamine, an organic heterotetracyclic compound and a methyl sulfide. It is a conjugate base of a pergolide(1+).
Classification
Small molecule
Drug classergot alkaloid deriviatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
Identifiers
PDB—
CAS-ID66104-22-1
RxCUI—
ChEMBL IDCHEMBL531
ChEBI ID63617
PubChem CID47811
DrugBankDB01186
UNII ID24MJ822NZ9 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HTR2B
HTR2B
ADRA2B
ADRA2B
DRD3
DRD3
DRD4
DRD4
HTR1B
HTR1B
HTR1D
HTR1D
DRD1
DRD1
DRD5
DRD5
HTR2A
HTR2A
HTR1A
HTR1A
HTR2C
HTR2C
ADRA2C
ADRA2C
DRD2
DRD2
HTR7
HTR7
ADRA2A
ADRA2A
HTR6
HTR6
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
3357
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Q6P523
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Pergolide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,290 documents
View more details
Safety
Black-box Warning
Black-box warning for: Permax
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
726 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use